Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) shares fell 0.9% during mid-day trading on Friday . The stock traded as low as $10.79 and last traded at $10.7960. Approximately 100 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 5,100 shares. The stock had previously closed at $10.89.
Drugs Made in America Acquisition Price Performance
The firm has a 50-day moving average of $10.86 and a 200-day moving average of $10.67.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Further Reading
- Five stocks we like better than Drugs Made in America Acquisition
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
